glp 1 kidney protection Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic disease through dampening the receptor for advanced glycation end products–induced inflammation Glucagon-like Peptide-1 Receptor Agonists: New

Everyone gets it, to be honest

After adjusting for factors like age and cardiovascular disease, researchers found that people on GLP-1 drugs were 16% less likely to develop epilepsy

News & World Report, Mental Floss, United Press ...

In addition to blood sugar control, Meglutide naturally suppresses appetite by acting on the brains appetite centers, helping reduce cravings and prolong satiety

In patients tolerating canagliflozin 100 mg once daily who have an eGFR of 60 mL/min/1.73 m 2 or greater and require additional glycemic control, the dose can be increased to 300 mg once daily

Chronic alcohol use drives neuroinflammation swelling and immune activation in the brain that perpetuates craving cycles and impairs decision-making